title: [Clinical and microbiological characteristics of Staphylococcus aureus infections in infectious diseases hospital Iaşi].
abstract: We assessed clinical and microbiological characteristics of Staphylococcus aureus (SA) infections in hospitalized patients during a period of three years (October 2005 - October 2008) in the Clinic Hospital of Infectious Diseases Iaşi.
  
  
  METHODS
  The study included 169 patients with SA infections (sepsis, meningitis, skin infections and urinary tract infections). MiniAPI system ID 32 STAPH was used for identification and antibiotic susceptibility was assessed by ATB STAPH method and by E-test for oxacillin and vancomycin.
  
  
  RESULTS
  The rate of methicillin resistance (MR) was 48%, all strains being susceptible to linezolid, vancomycin, teicoplanin. In our study MRSA was susceptible in approximately 94% of cases to clindamycin and cotrimoxazole. Infections were defined as nosocomial in 51% of patients with a rate of MR of 52% and community-acquired in 49% with a rate of MR of 23% (p = 0.001). Clinical profile was: localized infection in 41% of patients with MRSA and systemic infection (sepsis with at least one organ involvement or bacteremia) in 59% of patients with MRSA infections (p = 0.53). Initial treatment was inadequate in 46% of MRSA infections. One third of strains had MIC of vancomycin 2 mg/mL.
  
  
  CONCLUSIONS
  The high level of methicillin resistance of S. aureus straints isolated from infections (48 %) justifies a particular approach of initial antistaphylococcal therapy.
authors.affiliation: Universitatea de Medicina şi Farmacie Gr. T. Popa Iaşi, Facultatea de Medicina, Disciplina de Boli Infecţioase.
authors.forename: Simona Magdalena
authors.initials: SM
authors.lastname: Petrache
authors.forename: Egidia
authors.initials: E
authors.lastname: Miftode
authors.forename: Daniela
authors.initials: D
authors.lastname: Leca
authors.forename: Olivia
authors.initials: O
authors.lastname: Dorneanu
authors.forename: V
authors.initials: V
authors.lastname: Luca
mesh_terms: D000081:Acetamides / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000453:epidemiology / Q000382:microbiology; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology; D004359:Drug Therapy, Combination; D055819:Hospitals, Isolation / Q000706:statistics & numerical data*; D006785:Hospitals, University; D006801:Humans; D007297:Inpatients / Q000706:statistics & numerical data*; D000069349:Linezolid; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D023303:Oxazolidinones / Q000627:therapeutic use; D012189:Retrospective Studies; D012383:Romania / Q000453:epidemiology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000302:isolation & purification*; D017334:Teicoplanin / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D017334:Teicoplanin; D014640:Vancomycin; D000069349:Linezolid